Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II
Donald Basel
30 participants
Aug 1, 2016
INTERVENTIONAL
Conditions
Summary
The investigators wish to determine the time to disease progression for benign neurofibromas treated with Levulan Kerastick topical photosensitizer and red light photodynamic therapy (PDT) in patients with neurofibromatosis type 1 (NF1). The investigators also wish to measure tumor size for control and treatment tumors in order to gain insights into tumor growth rates.
Eligibility
Inclusion Criteria7
- Patient is 14 years or older.
- Diagnosed NF1, determined by American Academy of Neurology Guidelines (see Diagnosis section).
- Tumor Location: cutaneous, trunk, or limbs only.
- Tumor Type: superficial dermal neurofibromas ≤4mm deep.
- Patient has provided written informed consent.
- Patient is willing to and can comply with study follow-up requirements.
- Absence of any other malignancy.
Exclusion Criteria7
- Life expectancy less than 3 years.
- Pregnancy.
- Cutaneous photosensitivity to the wavelengths used to active PDT.
- A diagnosis of porphyria.
- Allergy to aminolevulinic acid or any of the topical solution vehicle components.
- Previous chemotherapy within 6 weeks of proposed PDT.
- Other concurrent tumor therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug: Levulan Kerastick Drug: Topical placebo Device: Omnilux Revive Procedure: Photodynamic therapy Other: Tumor growth rate measurements
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02728388